KERX up +1.71% percent Today $KERX High is at 15.6
Post# of 39
Posted On: 11/17/2014 2:50:02 PM
KERX up +1.71% percent Today $KERX High is at 15.68 and the Low 15.41 with current volume of 303,422.
Recent News posted below.
Keryx Biopharmaceuticals KERX other info.
http://investorshangout.com/Keryx-Biopharmace...ERX-54563/
KERX Keryx Biopharmaceuticals Recent Headline News
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.28 (+0.68), KOS: 9.50 (-0.16), KIN: 8.94 (+0.20), VSAT: 66.21 (-1.40), RFMD: 13.49 (-0.08), EBAY: 54.87 (+0.51), TQNT: 22.45 (-0.15), IDIX: 24.50 (+0.05), SEMI: 17.01 (-0.42), VRTV: 47.17 (+1.02), THRX: 13.25 (+0.02), TBPH: 17.37 (-0.11), IMOS: 21.13 (-0.76), ELOS: 9.95 (-0.34), MU: 32.28 (-0.34), AR: 52.66 (+0.15), NCQ: 0.71 (+0.02), PBF: 27.54 (+0.45), LNG: 72.19 (+0.33), ATRA: 24.43 (+1.26), KERX: 15.21 (unch), NG: 2.92 (+0.04), AOI: 1.85 (unch), FWP: 21.80 (-0.59), BYD: 11.64 (-0.42), ALDW: 17.38 (+0.25), SUNE: 16.50 (-0.43), MRK: 59.51 (+0.44), AVEO: 0.98 (+0.04), AIG: 53.98 (+0.08)
Keryx Bio presents Ferric Citrate safety data at ASN meeting
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:01AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
GlobeNewswire - Sat Nov 15, 9:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"
today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week meeting in Philadelphia, PA. The results are consistent with those seen in the pivotal Phase 3 trial.
KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Fri Nov 14, 7:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
KERX: 15.21 (unch)
'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 40.35 (+0.98), GD: 142.21 (-0.45), LMT: 185.52 (-1.08), RTN: 103.14 (-1.49), DDD: 35.60 (+1.53), NOC: 135.83 (-0.24), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), GM: 32.49 (+0.70), PG: 87.52 (-0.59), CAT: 101.95 (+0.61)
Cramer's Lightning Round - I Curse The Day I Bought General Motors (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:18AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 10. Bullish Calls: Merck (NYSE: MRK ): Cramer prefers Merck to Procter & Gamble. Intel (NASDAQ: INTC ): "INTC is underrated...
GD: 142.21 (-0.45), LMT: 185.52 (-1.08), NOC: 135.83 (-0.24), DDD: 35.60 (+1.53), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), HPQ: 37.41 (+0.49), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), SSYS: 105.06 (+0.21), GM: 32.49 (+0.70), CAT: 101.95 (+0.61), LINE: 22.24 (-0.41), PG: 87.52 (-0.59)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.97 (-0.01), BIIB: 305.00 (-0.43), AMAG: 35.05 (+1.05), KERX: 15.21 (unch)
Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.33 (+0.01), SWIR: 38.56 (+0.25), PERI: 5.79 (+0.12), JIVE: 6.53 (-0.30), TREE: 46.55 (-0.85), KERX: 15.21 (unch), ECYT: 6.57 (+0.15), ADEP: 8.50 (-0.09), ABTL: 10.84 (-0.48), NDLS: 23.21 (-0.27), BSFT: 26.71 (-0.79), SW.TO: 43.62 (+0.45), CALD: 15.83 (-0.23), PLNR: 7.04 (+0.35)
Keryx's (KERX) CEO Ron Bentsur on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:50AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals (KERX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST
KERX: 15.21 (unch)
Keryx Biopharma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:36AM CST
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a third-quarter loss of $35.3 million.
KERX: 15.21 (unch)
Keryx Biopharmaceuticals EPS of -$0.38
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:04AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx" , today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.
KERX: 15.21 (unch)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST
CYNI: 2.71 (-0.04), AAP: 145.78 (+0.97), DNOW: 28.50 (+0.16), AAON: 20.48 (-0.48), CNQ: 35.74 (-0.26), HSP: 58.36 (+0.08), CNK: 35.63 (-0.03), AMSC: 0.98 (-0.05), AES: 13.71 (+0.24), MWIV: 157.95 (+2.90), BBG: 12.95 (-1.16), HZNP: 12.52 (+0.27), KATE: 28.87 (-0.06), MITL: 10.24 (+0.12), AEE: 43.04 (+0.83), HSIC: 130.63 (+0.48), HII: 107.98 (+0.13), NAVB: 1.26 (+0.10), CECE: 14.08 (-0.46), AKRX: 37.88 (-0.33), COTY: 19.02 (-0.13), GOLD: 69.25 (+0.50), IT: 86.06 (+0.01), HNR: 2.89 (-0.10), KERX: 15.21 (unch), CECO: 5.69 (-0.20), HSC: 19.94 (+0.44), AMRC: 8.03 (-0.06), KLIC: 13.80 (-0.16), GEO: 39.30 (-0.62), AINV: 8.18 (-0.01), BCE: 47.39 (+0.52), AZN: 72.44 (-0.41), BCRX: 10.21 (+0.14), CPN: 23.45 (-0.15), BR: 45.10 (+0.03), FUR: 16.96 (+0.11), LIN: 24.00 (-0.04), LMIA: 13.88 (+0.16), CDW: 32.81 (-0.14), CVC: 18.70 (+0.16), AAWW: 41.26 (-0.35), GNRC: 41.92 (+0.05), MPEL: 25.99 (-0.54), DTV: 86.99 (-0.56), APA: 72.41 (-0.94), CRZO: 50.25 (-1.34), BKCC: 8.94 (unch), ERJ: 36.95 (+0.19), AMCX: 62.38 (+0.52), LPI: 17.15 (-0.56), HAIN: 108.29 (+0.02), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.57 (+0.53), FUN: 46.74 (-0.12), BDBD: 9.81 (+0.14)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 88.24 (+0.13), ACT: 245.62 (+1.85), HSP: 58.36 (+0.08), KERX: 15.21 (unch)
Keryx Biopharmaceuticals Up 9.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Mon Nov 03, 11:18AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on October 2nd, 2014 at $15.03. In approximately 1 month, Keryx Biopharmaceuticals has returned 9.68% as of today's recent price of $16.48.
KERX: 15.21 (unch)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.03 (-1.03), CLVS: 53.98 (-0.91), ARWR: 5.92 (-0.12), ACHN: 13.25 (-0.72), MRK: 59.51 (+0.44), RTRX: 9.45 (-0.45), RGLS: 16.80 (-0.40), EPZM: 22.68 (-0.29), AGIO: 84.96 (+0.90), RMTI: 10.55 (+0.03), ARNA: 4.53 (unch), KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
KERX: 15.21 (unch)
Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.04 (+0.24), CYTR: 2.78 (-0.01), KERX: 15.21 (unch)
Recent News posted below.
Keryx Biopharmaceuticals KERX other info.
http://investorshangout.com/Keryx-Biopharmace...ERX-54563/
KERX Keryx Biopharmaceuticals Recent Headline News
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 21.28 (+0.68), KOS: 9.50 (-0.16), KIN: 8.94 (+0.20), VSAT: 66.21 (-1.40), RFMD: 13.49 (-0.08), EBAY: 54.87 (+0.51), TQNT: 22.45 (-0.15), IDIX: 24.50 (+0.05), SEMI: 17.01 (-0.42), VRTV: 47.17 (+1.02), THRX: 13.25 (+0.02), TBPH: 17.37 (-0.11), IMOS: 21.13 (-0.76), ELOS: 9.95 (-0.34), MU: 32.28 (-0.34), AR: 52.66 (+0.15), NCQ: 0.71 (+0.02), PBF: 27.54 (+0.45), LNG: 72.19 (+0.33), ATRA: 24.43 (+1.26), KERX: 15.21 (unch), NG: 2.92 (+0.04), AOI: 1.85 (unch), FWP: 21.80 (-0.59), BYD: 11.64 (-0.42), ALDW: 17.38 (+0.25), SUNE: 16.50 (-0.43), MRK: 59.51 (+0.44), AVEO: 0.98 (+0.04), AIG: 53.98 (+0.08)
Keryx Bio presents Ferric Citrate safety data at ASN meeting
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:01AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
GlobeNewswire - Sat Nov 15, 9:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"
today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week meeting in Philadelphia, PA. The results are consistent with those seen in the pivotal Phase 3 trial. KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Fri Nov 14, 7:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
KERX: 15.21 (unch)
'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 40.35 (+0.98), GD: 142.21 (-0.45), LMT: 185.52 (-1.08), RTN: 103.14 (-1.49), DDD: 35.60 (+1.53), NOC: 135.83 (-0.24), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), GM: 32.49 (+0.70), PG: 87.52 (-0.59), CAT: 101.95 (+0.61)
Cramer's Lightning Round - I Curse The Day I Bought General Motors (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:18AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 10. Bullish Calls: Merck (NYSE: MRK ): Cramer prefers Merck to Procter & Gamble. Intel (NASDAQ: INTC ): "INTC is underrated...
GD: 142.21 (-0.45), LMT: 185.52 (-1.08), NOC: 135.83 (-0.24), DDD: 35.60 (+1.53), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), HPQ: 37.41 (+0.49), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), SSYS: 105.06 (+0.21), GM: 32.49 (+0.70), CAT: 101.95 (+0.61), LINE: 22.24 (-0.41), PG: 87.52 (-0.59)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.97 (-0.01), BIIB: 305.00 (-0.43), AMAG: 35.05 (+1.05), KERX: 15.21 (unch)
Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.33 (+0.01), SWIR: 38.56 (+0.25), PERI: 5.79 (+0.12), JIVE: 6.53 (-0.30), TREE: 46.55 (-0.85), KERX: 15.21 (unch), ECYT: 6.57 (+0.15), ADEP: 8.50 (-0.09), ABTL: 10.84 (-0.48), NDLS: 23.21 (-0.27), BSFT: 26.71 (-0.79), SW.TO: 43.62 (+0.45), CALD: 15.83 (-0.23), PLNR: 7.04 (+0.35)
Keryx's (KERX) CEO Ron Bentsur on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:50AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals (KERX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST
KERX: 15.21 (unch)
Keryx Biopharma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:36AM CST
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a third-quarter loss of $35.3 million.
KERX: 15.21 (unch)
Keryx Biopharmaceuticals EPS of -$0.38
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:04AM CST
KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"
, today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013. KERX: 15.21 (unch)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST
CYNI: 2.71 (-0.04), AAP: 145.78 (+0.97), DNOW: 28.50 (+0.16), AAON: 20.48 (-0.48), CNQ: 35.74 (-0.26), HSP: 58.36 (+0.08), CNK: 35.63 (-0.03), AMSC: 0.98 (-0.05), AES: 13.71 (+0.24), MWIV: 157.95 (+2.90), BBG: 12.95 (-1.16), HZNP: 12.52 (+0.27), KATE: 28.87 (-0.06), MITL: 10.24 (+0.12), AEE: 43.04 (+0.83), HSIC: 130.63 (+0.48), HII: 107.98 (+0.13), NAVB: 1.26 (+0.10), CECE: 14.08 (-0.46), AKRX: 37.88 (-0.33), COTY: 19.02 (-0.13), GOLD: 69.25 (+0.50), IT: 86.06 (+0.01), HNR: 2.89 (-0.10), KERX: 15.21 (unch), CECO: 5.69 (-0.20), HSC: 19.94 (+0.44), AMRC: 8.03 (-0.06), KLIC: 13.80 (-0.16), GEO: 39.30 (-0.62), AINV: 8.18 (-0.01), BCE: 47.39 (+0.52), AZN: 72.44 (-0.41), BCRX: 10.21 (+0.14), CPN: 23.45 (-0.15), BR: 45.10 (+0.03), FUR: 16.96 (+0.11), LIN: 24.00 (-0.04), LMIA: 13.88 (+0.16), CDW: 32.81 (-0.14), CVC: 18.70 (+0.16), AAWW: 41.26 (-0.35), GNRC: 41.92 (+0.05), MPEL: 25.99 (-0.54), DTV: 86.99 (-0.56), APA: 72.41 (-0.94), CRZO: 50.25 (-1.34), BKCC: 8.94 (unch), ERJ: 36.95 (+0.19), AMCX: 62.38 (+0.52), LPI: 17.15 (-0.56), HAIN: 108.29 (+0.02), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.57 (+0.53), FUN: 46.74 (-0.12), BDBD: 9.81 (+0.14)
Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 88.24 (+0.13), ACT: 245.62 (+1.85), HSP: 58.36 (+0.08), KERX: 15.21 (unch)
Keryx Biopharmaceuticals Up 9.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Mon Nov 03, 11:18AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on October 2nd, 2014 at $15.03. In approximately 1 month, Keryx Biopharmaceuticals has returned 9.68% as of today's recent price of $16.48.
KERX: 15.21 (unch)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.03 (-1.03), CLVS: 53.98 (-0.91), ARWR: 5.92 (-0.12), ACHN: 13.25 (-0.72), MRK: 59.51 (+0.44), RTRX: 9.45 (-0.45), RGLS: 16.80 (-0.40), EPZM: 22.68 (-0.29), AGIO: 84.96 (+0.90), RMTI: 10.55 (+0.03), ARNA: 4.53 (unch), KERX: 15.21 (unch)
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
KERX: 15.21 (unch)
Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.04 (+0.24), CYTR: 2.78 (-0.01), KERX: 15.21 (unch)
(0)
(0)